Abstract

Purpose Graft versus Host Disease (GVHD) typically affects the ocular surface, with a presentation resembling Dry Eye Disease (DED). Although the etiopathology is not completely known, the conjunctiva might be a key site of T-cell activation. The differential diagnosis might be tricky at early stages, because of the lack of dedicated clinical and laboratory tests. To meet these needs, we evaluated the suitability of ocular surface matrix metalloproteinase-9 (MMP-9) clinical test. Methods Consecutive GVHD patients, referred to IRCCS San Raffaele Scientific Institute, were recruited. DED patients served as controls. MMP-9 was tested through InflammaDry immunoassay kit in both groups; Ocular Surface Disease Index (OSDI) questionnaire, tear osmolarity, fluorescein Tear Break-up Time (TBUT), corneal and conjunctival staining, and Schirmer test I were also collected. Parametric and nonparametric statistical tests were used to analyze the intergroup differences; Receiver Operating Characteristics (ROC) curve analysis was carried out to perform sensitivity and specificity evaluations. Results Forty-five GVHD and 40 DED patients were included. MMP-9 expression was significantly higher in GVHD group than in DED (84.4% vs 33%, p ≤ 0.001). Corneal and conjunctival staining scores resulted worse in GVHD than in DED (0.95 ± 1.16 vs 0.40 ± 0.63, p=0.02; 0.77 ± 0.42 vs 0.40 ± 0.49, p=0.0005, respectively). No significant differences regarded the other collected parameters. GVHD group was characterized by positive correlations between MMP-9 and conjunctival staining (rho = 0.55, p=0.0002) and between MMP-9 and OSDI (rho = 0.3, p=0.01); a faint inverse correlation was found between MMP-9 and Schirmer test (rho = −0.25, p=0.04). Conclusion MMP-9 has a role in physiologic cellular remodeling; when a proinflammatory stimulus occurs, MMP-9 molecules are overreleased in the extracellular matrix. The positive expression of MMP-9 in GVHD may be interpreted as the consequence of a T-cell aggression against self-antigens and may be considered a reliable biomarker to detect ocular surface inflammation in GVHD, even in early stages of the disease.

Highlights

  • Ocular chronic graft versus host disease (GVHD) often affects patients undergoing allogeneic hematopoietic stemcell transplantation [1,2,3,4].e advancements in human leukocyte antigen (HLA) matching techniques and the improvements in posttransplant treatments made allo-HSCT the gold-standard cure for life-threatening hematologic malignancies [5, 6]

  • E period lasting from allo-HSCT to the occurrence of ocular GVHD was of 21.4 ± 12.2 months; no statistical significance was found between matrix metalloproteinase-9 (MMP-9) positive and MMP9 negative patients (22.3 ± 11.8 months vs 17.2 ± 14.5 months; p 0.3)

  • E frequency of the expression of Matrix metalloproteinases (MMPs)-9 resulted in significantly higher GVHD than in dry eye disease (DED) (84.4% vs 33%, p ≤ 0.001). e Receiver Operating Characteristics (ROC) curve analysis demonstrated an area under the curve equal to 0.897 (95% confidence interval 0.812–0.953; sensitivity 84.4%; specificity 95%) (Figure 1)

Read more

Summary

Introduction

Ocular chronic graft versus host disease (GVHD) often affects patients undergoing allogeneic hematopoietic stemcell transplantation (allo-HSCT) [1,2,3,4].e advancements in human leukocyte antigen (HLA) matching techniques and the improvements in posttransplant treatments made allo-HSCT the gold-standard cure for life-threatening hematologic malignancies [5, 6]. Ocular chronic graft versus host disease (GVHD) often affects patients undergoing allogeneic hematopoietic stemcell transplantation (allo-HSCT) [1,2,3,4]. Different from the multifactorial etiology of dry eye disease (DED), [9] the pathogenic mechanism below the development of GVHD is mainly characterized by the aggression of the transplanted immune cells against host antigens. GVHD diagnosis is mainly performed considering the systemic clinical signs, and, to date, no ocular-specific biomarkers are available for the ophthalmologists. For this reason, especially considering the early GVHD stages, the differential diagnosis with other forms of DED (e.g., iatrogenic DED) may be extremely challenging

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call